In the BioHarmony Drug Report Database

"Preview" Icon

Capsaicin

Qutenza (capsaicin) is a small molecule pharmaceutical. Capsaicin was first approved as Qutenza on 2009-05-15. It is used to treat diabetic neuropathies, herpes zoster, and neuralgia in the USA. It has been approved in Europe to treat neuralgia. The pharmaceutical is active against transient receptor potential cation channel subfamily V member 1. In addition, it is known to target transient receptor potential cation channel subfamily V member 1, cystic fibrosis transmembrane conductance regulator, potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily C member 1, potassium voltage-gated channel subfamily A member 1, and potassium voltage-gated channel subfamily A member 2. Dermacinrx lexitral pharmapak’s patents are valid until 2030-03-26 (FDA).

 

Trade Name

 

Qutenza
 

Common Name

 

capsaicin
 

ChEMBL ID

 

CHEMBL294199
 

Indication

 

diabetic neuropathies, herpes zoster, neuralgia
 

Drug Class

 

Image (chem structure or protein)

Capsaicin structure rendering